Publication | Open Access

Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands

Acute TreatmentThrombosisVenous ThrombosisCost-effectiveness AnalysisHealth EconomicsMedicinePatient SafetyOutcomes ResearchPharmacoeconomicsPharmacotherapyVenous ThromboembolismPlatelet AntagonistStrokeAnticoagulantEmergency Medicine